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1. Introduction
Calcific Aortic Valve Disease (CAVD) occurs in >2% of the population over 65 years of age
and often leads to valvular stenosis that necessitates valve replacement [1]. CAVD is a pro‐
gressive disease, often manifesting first as aortic valve sclerosis and later developing into
stenosis and valve dysfunction [2]. The specific molecular and cellular mechanisms of
CAVD initiation and advancement are not well defined, and inhibitors of CAVD progres‐
sion have not been identified. The current standard of treatment for CAVD is aortic valve
replacement [3]. Presently, there are no pharmacologic-based treatments for CAVD, and
new therapeutic approaches for CAVD are needed. The majority of aortic valves that are re‐
placed have congenital malformations, such as bicuspid aortic valve (BAV), establishing a
link between valve development and disease mechanisms [4].
The molecular mechanisms of CAVD include activation of signaling pathways implicated in
both heart valve development (valvulogenesis) and bone development (osteogenesis) [5-8].
These include activation of regulators of progenitor specification, cell proliferation, and dif‐
ferentiation. Heart valves and bone are complex connective tissues with compartmentalized
ECM produced by specialized cell types. Over the past several years, extensive progress has
been made in defining molecular regulatory mechanisms in heart valve and bone develop‐
ment (Reviewed in [8-10]). Strikingly, regulatory pathways that control development of car‐
tilage, tendon and bone also are active in developing valves [8, 11]. In addition, recent
studies have reported induction of molecular regulators of valvulogenesis and osteogenesis
in CAVD [7, 12-14]. However, it is not known if these developmental mechanisms have rep‐
arative functions or contribute to the progression of CAVD.
Here we review molecular mechanisms of valve and bone development as they relate to mo‐
lecular mechanisms of CAVD. Recent studies have provided evidence for the involvement
of specific regulatory pathways in CAVD as activators or inhibitors of disease progression.
© 2013 Wirrig and Yutzey; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Additional research in animal models and human patient specimens is necessary to deter‐
mine the detrimental molecular regulatory pathways that promote CAVD progression and
also beneficial pathways that potentially inhibit CAVD. In the future, manipulation of these
pathways could be exploited therapeutically in the treatment of patients with CAVD or with
aortic valve sclerosis that precedes calcification.
Figure 1. Molecular pathways active during endocardial cushion development and valve stratification are reacti‐
vated in CAVD. (A) Early stages of OFT cushion development are marked by ECM deposition, EMT, and neural crest cell in‐
filtration. Factors necessary for EMT and mesenchymal cell function are expressed. (B) During late embryonic development
and early postnatal development, the aortic valve becomes stratified and possesses three ECM layers. Factors necessary for
ECM remodeling are active at this stage. (C) In CAVD, the ECM remodels and the valve becomes thickened. Calcification
(black nodules) is typically observed in the collagen-rich fibrosa layer. Many factors expressed during OFT cushion develop‐
ment and valve stratification are reactivated during disease. Furthermore, osteogenic factors involved in bone develop‐
ment are also observed in CAVD. Please see text for details and references. OFT = outflow tract, EMT = epithelial-to-
mesenchymal transition, ECM = extracellular matrix, CAVD = calcific aortic valve disease.
2. The cellular and molecular regulation of valve development
2.1. Overview of valve development
Valve development begins with the formation of endocardial cushions in the atrioventricu‐
lar (AV) canal and outflow tract (OFT) of the primitive heart tube, which occurs at embryon‐
ic day (E)9-10 in mice, E3 in chickens, and E31-35 in humans [8]. The first evidence of
endocardial cushion formation is the separation of the endocardium and overlying myocar‐
dium in the AV canal by expansion of the cardiac jelly through increased expression of hya‐
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luronan (Figure 1) [15]. These swellings are invested with mesenchymal cells that arise from
endothelial-to-mesenchymal transformation (EMT) of the endocardium [16]. Similar swel‐
ling and induction of EMT occur approximately a day later in the cardiac OFT cushions that
will contribute to the semilunar valves [17]. Endocardial EMT is induced by signaling mole‐
cules, including bone morphogenetic proteins (BMPs), emanating from the adjacent myocar‐
dium in the AVC and OFT [8, 18-20]. Once established, the endocardial cushions expand
through increased extracellular matrix (ECM) production and cell proliferation of mesen‐
chymal and endothelial cells. The AV cushions subsequently fuse to separate right and left
cardiac channels. In addition, lateral cushions are induced in the AV sulcus that will give
rise to the mural leaflets of the mitral and tricuspid valves [21]. Neural crest cells (NCCs)
migrate into the cushions of the cardiac OFT, contributing to the septum between the aortic
and pulmonic roots and also to the morphogenesis of individual semilunar valve leaflets
[21, 22]. At this point, distinct primordia of individual valve leaflets become apparent and
proliferation of valve interstitial cells (VICs) is reduced [23]. Valve morphogenesis occurs
with elongation and thinning of the valve primordia, in addition to ECM remodeling and
stratification. In general, the development of the AV and semilunar (SL) valves is similar,
but there are some differences in the sources of cells and structure of the resulting leaflets [8,
10, 11, 24]. In mature SL and AV valves, the ECM is stratified into collagen-rich fibrosa, pro‐
teoglycan-rich spongiosa, and elastin-rich (atrialis-ventricularis) layers oriented relative to
blood flow [24].
2.2. Embryonic origins of valve cell lineages
The primary embryonic source of adult semilunar valve interstitial cells is the endothelial-
derived cells of the endocardial cushions, that arise as a result of EMT as determined by
Tie2-Cre lineage tracing in mice [23, 25]. Since the cardiac OFT is derived from the secon‐
dary heart field (SHF), semilunar VICs derived from OFT endocardium also are SHF-de‐
rived [20, 26]. NCC-derived cells are present in adult mouse semilunar valve leaflets as
demonstrated by cell lineage tracing with Wnt1-Cre [27]. These cells are predominant
throughout the aortic and pulmonic valve leaflets, but are enriched in the leaflets adjacent to
the aorticopulmonary septum, which also is derived from NCCs [21, 28]. NCCs are required
for semilunar valve morphogenesis and remodeling, likely by providing signals necessary
for cell lineage differentiation and leaflet maturation [29, 30]. Another potential source of
VICs is the epicardium, which contributes cells to the parietal leaflets of AV valves [31].
However, epicardial-derived cells (EPDCs) have not been not reported to contribute to the
semilunar valves, based on Wt1-Cre fatemapping studies [31, 32]. Recent studies have re‐
ported that bone marrow-derived stem cells (BMSCs) are present in the developing and ma‐
ture semilunar valves [33, 34]. Additional work is necessary to determine if these cells have
lineages and functions distinct from the predominant endocardial cushion-derived or neural
crest-derived VICs. It is possible that valve cell lineages derived from different developmen‐
tal sources have distinct functions in normal and diseased aortic valves, but this has not yet
been demonstrated. The sources of increased proliferative cells in diseased valves are rela‐
tively unknown, but could be any of these embryonic sources or, alternatively, an infiltrat‐
ing cell type.
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2.3. Transcription factors involved in valve development
Several transcription factors have been implicated in various processes of endocardial cush‐
ion formation and EMT (reviewed in [8, 35]). Notch pathway function in EMT is dependent
on the transcription factor RBPJ, which activates expression of the bHLH transcription factor
snail1 (Snai1) in endothelial cells [36]. Snai1 represses ve-cadherin gene expression, and loss
of Snai1 in endothelial cells inhibits endocardial cushion formation [36, 37]. The mesenchy‐
mal valve progenitor cells of the endocardial cushions express several transcription factors
characteristic of a variety of embryonic mesenchymal progenitor populations. These factors
include, Twist1, Msx1/2, Tbx20, and Sox9 [18, 38-41]. Gain and loss of function studies have
demonstrated critical roles for Tbx20, Twist1, and Sox9 in endocardial cushion mesenchy‐
mal cell proliferation [38-40]. Twist1 promotes tbx20 expression directly and also regulates
several genes associated with cell proliferation and migration [38, 42]. After endocardial
cushion fusion and formation of valve primordia, mesenchymal genes, notably twist1 [43],
are down-regulated and cell proliferation is decreased [23, 24, 44]. In normal adult valves,
there is little to no cell proliferation [24, 44], and expression of valve developmental tran‐
scription factors including Twist1, Sox9, and Msx2 is not detectable [13]. However, all of
these factors are predominantly expressed in adult human CAVD (see below).
Additional regulatory pathways control heart valve ECM remodeling and compartmentali‐
zation. Loss of NFATc1 results in defective remodeling of the AV and SL valves in mice,
with embryonic lethality by E14.5 [45, 46]. EMT occurs with loss of NFATc1, but valve pri‐
mordia fail to remodel and mature ECM molecules are not expressed in null mice or in cul‐
tured VICs with inhibition of receptor activator of nuclear factor κ-B ligand (RANKL) or
calcineurin signaling upstream of NFATc1 activation [45, 47]. In addition to being required
for endocardial cushion mesenchymal proliferation, Sox9 also promotes cartilage-like ECM
gene expression in valve progenitor cells [48]. In late stage mouse embryos, loss of Sox9 in
remodeling valves results in reduced proteoglycan expression, and Sox9 haploinsufficiency
in adults leads to valve calcification [40, 49]. Conversely, the bHLH transcription factor
Scleraxis, critical for tendon development, promotes expression of elastic/tendon-like matrix
genes in cultured valve progenitor cells [48]. Loss of Scleraxis in mice is not lethal, but heart
valve defects similar to myxomatous valve disease occur in these animals [50]. Little is
known of the transcriptional regulatory mechanisms that control the development of the
valve fibrosa layer, which is most critically involved in CAVD.
2.4. Signaling pathways in valve development
Several essential embryonic signaling pathways have been implicated in endocardial cush‐
ion formation and EMT (Table 1) (reviewed in [8]). Transforming growth factor (TGF)β sig‐
naling was the first pathway implicated in endocardial cushion formation and is required
for EMT in chicken and mouse embryonic systems (reviewed in [16]). BMP signaling from
the myocardium is required in endothelial cells for the initiation of EMT in the AV canal,
and BMP2 and 4 are the predominant ligands involved in endocardial cushion development
[18-20]. Notch signaling also is required for EMT as described above. Moreover, Notch sig‐
naling is required for expression of TGFβ ligands and receptors, in addition to activating
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BMP signaling, which promotes mesenchymal cell invasion [36, 51]. Likewise, vascular en‐
dothelial growth factor (VEGF) signaling promotes endocardial cushion endothelial cell pro‐
liferation and EMT [47, 52]. Furthermore, targeted mutagenesis of β-catenin has implicated
Wnt/β-catenin signaling in endocardial cushion EMT and mesenchymal proliferation [53,
54]. Thus multiple pathways are involved in endocardial cushion EMT and mesenchymal
cell proliferation. However, the intersection and specific cellular functions of these pathways
have not been fully determined.
A. Signaling pathways
Role in valvulogenesis Role in osteogenesis Role in CAVD
VEGF
EMT, endothelial
proliferation
angiogenesis angiogenesis
Notch EMT Inhibit OB differentiation represses calcification
TGFβ EMT bone homeostasis promotes VIC calcification
FGF
promotes tenascin
expression
OB proliferation,
differentiation
blocks VIC calcification
BMP EMT, PG expression promotes OB specification active in CAVD
Wnt/β-catenin EMT, fibrosa expression promotes OB differentiation active in CAVD
RANKL ECM remodeling OC differentiation promotes VIC calcification
B. Transcription factors
Role in valvulogenesis Role in osteogenesis Role in CAVD
Twist1 ECC proliferation, migration represses differentiation active in CAVD
Msx2 EMT, proliferation present in progenitors, OB active in CAVD
Sox9 proliferation, PG expression
progenitor proliferation,
cartilage differentiation
active in CAVD
inhibits calcification
NFATc1
endothelial proliferation,
ECM remodeling
promotes OC differentiation
promotes OB differentiation
reported in CAVD
Runx2 not present promotes OB differentiation active in CAVD
Osterix not present promotes OB differentiation reported in CAVD
aPlease see text for details and references. bAbbreviations used: CAVD=calcific aortic valve dis‐
ease; ECM=extracellular matrix; EMT=endothelial to mesenchymal transition; OB=osteoblast;
OC=osteoclast; PG=proteoglycan; VIC=valve interstitial cell.
Table 1. Signaling pathways and transcription factors involved in valvulogenesis, osteogenesis, and CAVDa, b
Many of the signaling pathways important for endocardial cushion formation also have lat‐
er functions in valve lineage diversification, remodeling, and stratification. However, these
functions have been difficult to elucidate due to limitations of available genetic tools and
Developmental Pathways in CAVD
http://dx.doi.org/10.5772/54356
63
critical requirements for these same regulatory pathways in endocardial cushion formation.
BMP signaling, as indicated by phosphorylation of the intermediate signaling molecules
Smad1/5/8, is active throughout endocardial cushion mesenchymal cells, is associated with
mesenchymal cell proliferation [55], and also is active later in valve cell lineage diversifica‐
tion [48]. BMP Receptor II mutations and conditional mutagenesis results in thickening of
semilunar valve leaflets at late fetal stages [56, 57]. Loss of inhibitory Smad6 leads to in‐
creased BMP signaling, in addition to thickening of valve leaflets and CAVD in adult ani‐
mals [58]. Studies in explanted avian valve progenitors have revealed antagonistic
regulatory roles for BMP and fibroblast growth factor (FGF) signaling in promoting diversi‐
fied ECM gene expression, conserved with mechanisms that control cartilage and tendon
lineage development [11, 48, 59]. Wnt pathway activation is evident throughout the remod‐
eling AV and semilunar valve primordia, as indicated in TopGal reporter mice [60]. Multi‐
ple Wnt ligands are expressed during valvulogenesis, but the function of Wnt signaling in
heart valve remodeling has not yet been determined [60]. Thus, additional in vivo studies
are necessary to determine the specific functions and intersecting regulatory mechanisms of
these critical signaling pathways in valve leaflet development and also to determine specific
contributions to valve degeneration and disease.
The later stages of heart valve development are characterized by leaflet elongation, ECM re‐
modeling, and stratification, all of which are critical for mature valve structure and function
[24]. Limited information is available on the regulation of these processes, but several regula‐
tory pathways have been implicated in late valve remodeling and morphogenesis. Strikingly
these same pathways have been implicated in adult CAVD (see below). RANKL, expressed by
valve endothelial cells, promotes ECM remodeling and Cathepsin K (Ctsk) expression by
NFATc1 in a mechanism partially conserved with osteoclast differentiation and function [11,
47, 61]. The signaling mechanisms that control stratification and ECM organization of the
valve leaflets are relatively unknown. Notch signaling is localized on the ventricularis surface
of the remodeling aortic valve in mice [62], and Wnt/β-catenin signaling is active throughout
aortic valve primordia at late gestation and in a subpopulation of VICs after birth [60]. Like‐
wise, Wnt signaling promotes expression of fibrosa genes periostin and matrix gla-protein (mgp)
in cultured chicken embryo aortic VICs, but a role in valve stratification or lineage diversifica‐
tion has not yet been established in vivo [60]. Additional studies are necessary to demon‐
strate the specific functions and potential biomechanical stimulation of these pathways in an
in vivo context. Since, both Notch and Wnt signaling pathways are required for initial stages
of endocardial cushion formation, it has been difficult to establish their roles in the later stages
of valvulogenesis in vivo using available conditional targeting approaches.
Bicuspid aortic valve is arguably the most common congenital heart malformation with an
incidence of 1-2% in the US adult population [63]. BAV often does not often manifest in
valve dysfunction in early life, but malformed aortic valves are predisposed to calcification.
Strikingly, the majority of stenotic aortic valves that are replaced in adults are congenitally
malformed [4]. However, the molecular and cellular mechanisms of BAV are not well de‐
fined. In humans, mutations in NOTCH1 are associated with BAV, but the mechanisms by
which valve leaflet number is regulated by Notch signaling have not yet been identified [64].
Likewise, Notch1 haploinsufficiency in mice leads to BAV at very low penetrance and there
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are likely to be additional factors necessary for congenital malformation of the aortic valve
leaflets [65]. Loss of the zinc finger transcription factor GATA5 in mice [66] and mutations in
human GATA5 [67] are associated with BAV with incomplete penetrance. Likewise eNOS
haploinsufficiency also leads to BAV, albeit with incomplete penetrance [68]. The mecha‐
nisms by which these genetic lesions lead to BAV in some individuals and not others are not
known. However, based on the expression and function of Notch1, GATA5, and eNOS in
endothelial cells, it is likely that these cells contribute to development of BAV in these mod‐
els. The link between BAV and CAVD could be due to similar regulatory mechanisms in de‐
velopment and disease or could, alternatively, result from induction of calcification in a
hemodynamically compromised congenitally malformed aortic valve (see other chapters for
a more complete discussion of BAV and CAVD).
2.5. Extracellular matrix composition and stratification of the developing valves
The mature valve leaflets are composed of stratified ECM with layered compartments of fi‐
brillar collagen, proteoglycan, and elastin (Figure 1) (reviewed in [10, 69]). During heart
valve remodeling, there is little proliferation of VICs, but the cells are highly synthetic and
produce multiple ECM proteins of the mature leaflets [24, 44]. The distinct layers of matrix
are integral to heart valve function and confer specific biomechanical properties to the valve
leaflets [69]. The regulatory mechanisms for ECM remodeling and stratification are not well
defined but are relevant to heart valve disease mechanisms. Periostin is required for colla‐
gen remodeling, and loss of periostin in mice leads to adult valve malformations and cardiac
dysfunction [70, 71]. Likewise, mutations in Collagen 1a2 or elastin haploinsufficiency also
result in aortic valve dysmorphogenesis and adult disease [72, 73]. Gene expression of CtsK,
a matrix remodeling enzyme expressed during heart valve elongation, is regulated by the
RANKL/NFATc1 regulatory pathway [47, 61]. Additional ECM remodeling enzymes, in‐
cluding matrix metalloproteinase (MMP)13, a collagenase, and Adam-TS5 and 9 proteogly‐
can proteases, also are expressed during late valve morphogenesis and have been implicated
in ECM maturation and organization [39, 74, 75]. Several ECM molecules required for nor‐
mal valve structure/function also are expressed during osteogenesis, and valve progenitors
have gene expression profiles similar to bone progenitors [43]. Osteopontin, osteonectin, and
periostin gene expression and collagen fiber deposition are increased during heart valve re‐
modeling [24, 43, 60]. However, the regulatory mechanisms for expression of these genes in
valve development are not well defined. These proteins also are induced and mislocalized in
pediatric and adult heart valve disease [13, 24, 70], but the pathways leading to their dysre‐
gulation have not yet been fully characterized.
3. Molecular mechanisms of osteogenesis
3.1. Overview of skeletal development
Many osteogenic regulatory interactions identified in developing bone also are active in
CAVD (Table 1). The regulatory hierarchies and ECM composition of the developing valves,
Developmental Pathways in CAVD
http://dx.doi.org/10.5772/54356
65
most notably the collagen rich fibrosa layer, are similar to those observed in osteoblast pre‐
cursor cells [43]. Both the bone substratum and valve ECM are composed primarily of fibril‐
lar collagen. Thus, it is not surprising that there are extensive similarities in their
composition and developmental regulation. Normally, heart valves do not progress to min‐
eralization, but striking similarities have been identified between osteogenic pathways that
regulate bone mineralization and CAVD mechanisms [7]. Thus the molecular understanding
of normal development of bone has clear implications for pathogenic mechanisms of con‐
nective tissue mineralization, including CAVD.
The osteogenic precursors of the developing axial skeleton and long bones of the limbs are
derived primarily from paraxial mesoderm of the developing somites and also lateral plate
mesoderm, the main source of cardiac precursor cells [76, 77]. Additional progenitors of the
craniofacial skeleton are derived from cranial neural crest [78]. Most axial skeletal elements
develop by endochondral bone formation that occurs through a cartilage intermediate [76,
77]. Alternatively, the craniofacial bones of the skull form through membranous ossification
in which condensed osteogenic progenitors differentiate directly into bone and do not go
through a cartilage intermediate [76]. The osteochondroprogenitors present in the axial and
appendicular skeletal elements develop into both bone and cartilage lineages [77, 79, 80]. Ex‐
tensive research over the past several years has defined transcriptional regulatory mecha‐
nisms and signaling events that control the development of cartilage and bone (Figure 2)
[79, 80].
Mature cartilage is composed predominantly of chondroitin sulfate proteoglycans that pro‐
vides cushioning and flexibility to cartilaginous structures [77, 81]. In addition, the proteo‐
glycan-rich ECM is angiostatic and mature cartilage is avascular [81]. Interestingly, the
predominant proteoglycan composition and lack of vasculature also are features of the ma‐
ture aortic valve leaflet spongiosa layer [82]. Likewise, the cartilage ECM inhibits minerali‐
zation, and a similar role has been hypothesized for the proteoglycan-rich matrix of the
aortic valve [49]. During normal axial bone development, osteoblasts from the laterally
placed periostium differentiate into trabecular bone, and secondary ossification centers at
the ends of the bone displace the growth plate hypertrophic cartilage [79, 80]. During bone
differentiation, hypertrophic cartilage cells must die for mineralization to occur in a process
of endochondral ossification, which could be related to dystrophic mechanisms of CAVD
[79, 80].
Bone cell lineage maturation goes through multiple stages defined by molecular regulatory
mechanisms that also are active in valve development and disease processes [80]. Osteo‐
chondroprogenitor cells express several mesenchymal transcription factors, including
Twist1, Msx2, and Sox9, that also are predominant in valve progenitor cells and diseased
aortic valves [79]. Immature pre-osteoblasts express high levels of fibrillar type 1 collagen, in
addition to periostin, osteonectin, and osteopontin, similar to normal differentiated VICs
[43, 60]. Differentiated osteoblasts are not yet mineralized but express the transcription fac‐
tor Runx2, in addition to osteocalcin and bone sialoprotein involved in bone mineralization
and also in valve calcification, [7, 80]. Later stage osteoblasts and osteocytes express the tran‐
scription factor Osterix (Osx), which is regulated by Runx2 and is required for mature bone
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formation [83]. Bone mineralization occurs with the deposition of calcium phosphate and
hydroxyapatite by osteocytes and is dependent on Runx2 and Osx function [80]. Bone ho‐
meostasis is maintained throughout life by the osteogenic activity of osteocytes and bone re‐
sorption activity of osteoclasts [80].
Figure 2. Hierarchies of signaling pathways and transcription factors regulate the differentiation of chondrogenic and
osteogenic progenitor cells during skeletal development. Early osteochondrogenic progenitor cells express BMPs,
Twist1, Msx1/2, and Sox9. Wnt/β-catenin signaling promotes pre-osteoblast differentiation while inhibiting chondro‐
cyte differentiation. In contrast, Notch signaling promotes cartilage differentiation and inhibits osteoblast differentia‐
tion. BMP signaling is further required for osteocyte differentiation in the final stages of bone maturation. Sox5, 6, and
9 are transcription factors crucial for maintaining the chondrogenic lineage, whereas, Runx2, Osx, and ATF4 are tran‐
scription factors necessary for osteoblast and osteocyte differentiation and maturation. Many of these factors are also
expressed during calcific aortic valve disease and have been implicated in pathologic calcification. Please see text for
details and references. Activating factors are shown in green, inhibitory factors are shown in red, and signaling path‐
ways are indicated in blue.
3.2. Transcriptional regulation of osteoblast lineage development and bone
differentiation
Twist1 is expressed early in the osteochondroprogenitor lineage and inhibits terminal differ‐
entiation of cartilage and bone [84]. In preosteoblasts, Twist1 binds to Runx2 and inhibits its
transcriptional activation of bone differentiation genes including osteocalcin [84]. Similarly,
Twist1 can inhibit cartilage differentiation by binding to Sox9 and preventing activation of
cartilage-specific gene expression [85]. Mutations in human TWIST1 cause Saethre-Chotzen
syndrome, characterized by premature bone differentiation evident in premature fusion of
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cranial sutures of the skull [86]. Msx2 also is involved in early mesenchymal stages of osteo‐
chondroprogenitor development and is down regulated during osteoblast differentiation
[79]. Persistent Msx2 expression in osteoblasts prevents differentiation and mineralization,
while antisense mRNA-mediated loss of Msx2 accelerates these processes [87]. Thus Msx2 is
expressed in osteoblast progenitor cells but has an inhibitory role in osteogenic differentia‐
tion. Together Twist1 and Msx2 act to maintain undifferentiated osteochondroprogenitors
during development.
Sox9 functions in the expansion of cartilage progenitors and promotes cartilage differentia‐
tion, while inhibiting bone differentiation [77, 80]. Sox9 is required for osteochondroproge‐
nitor lineage specification but is not expressed in differentiated osteoblasts [88]. At early
stages of cartilage lineage development, Sox9 promotes cell proliferation and later is re‐
quired for cartilage lineage differentiation [88]. BMP signaling induces Sox9 gene expression
in cartilage progenitor cells [89], and Sox9 regulates expression of cartilage marker genes
Col2a1 and aggrecan [90, 91]. Sox9 transcriptional activity can be inhibited by binding to
Twist1, thus inhibiting differentiation of early stage osteochondroprogenitor cells [85]. At
later stages of cartilage maturation, Sox9 inhibits Runx2 transcriptional activity, thus pro‐
moting hypertrophic cartilage and inhibiting osteogenic differentiation [92]. Thus downre‐
gulation of Sox9 is required in osteoblasts for differentiation and mineralization of bone.
Runx2, originally called Cbfa1, has been defined as a master regulatory gene in bone forma‐
tion [79, 93]. Gain and loss of function studies in mice demonstrate that Runx2 is both neces‐
sary and sufficient for osteoblast differentiation [93]. During bone development, Runx2
directly regulates osteocalcin gene expression [93]. Runx2 transcriptional function can be in‐
hibited by interaction with Twist1 and also by Hey1, downstream of Notch signaling [84,
94]. Mice lacking Runx2 lack mineralized bone, and haploinsufficiency of Runx2 results in
reduced bone formation in mice and humans [80]. Induction of a dominant negative form of
Runx2 in differentiated osteoblasts after birth also leads to reduced bone mineralization,
demonstrating a role for Runx2 in bone homeostasis and mineralization throughout life [95].
Runx2 has not been implicated in normal heart valve development, and its expression in de‐
veloping valves has not been reported, consistent with the lack of calcification in normal
valves. Likewise, in adult valves Runx2 is not normally expressed, but its expression is in‐
duced in CAVD in both humans and mice [13, 73]. The presence of Runx2 in diseased aortic
valves and association with calcification is consistent with a role in mineralization, as has
been established for bone cell lineages.
NFATc1 is a critical transcription factor in osteoclast differentiation and also has been impli‐
cated in osteoblast development [80, 96]. Osteoclasts, derived from a macrophage lineage,
have bone resorptive activity and are necessary for bone homeostasis [96]. During osteoclast
development, RANKL signaling induces activation of NFATc1, which promotes the tran‐
scription of bone matrix remodeling genes including CtsK and mmp9 [97, 98]. RANKL activi‐
ty in bone is antagonized by the receptor decoy osteoprotegerin (OPG) that promotes bone
calcification [99, 100]. In osteoblasts, NFATc1 promotes cell proliferation and also enhances
differentiation by cooperating with Osx to promote Col1a1 gene expression [101, 102]. Thus,
the balance of RANKL and OPG signaling acting on NFATc1 transcriptional function is a
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critical mediator of bone calcification and resorption [96]. A similar balance of OPG and
RANKL signaling in CAVD has been proposed [103]. While NFATc1 is a critical regulator of
heart valve remodeling during development and activates valvular CtsK expression [47, 61],
its role in CAVD and adult valve homeostasis has not been determined.
Additional transcription factors involved in bone differentiation are not generally found in
CAVD, although there are conflicting reports. Most notable is Osx, which is required for ter‐
minal differentiation of osteoblasts and mineralization of bone [83]. Osx, promotes expres‐
sion of collagen 1a1 and the matrix metalloproteinase mmp13, which also are upregulated in
aortic valve disease [73, 101, 104, 105]. Studies based on antibody staining demonstrate Osx
expression in Notch signaling-deficient calcified mouse valves [65] and human CAVD [106].
ATF4 is an additional transcription factor critical for bone differentiation, mineralization,
and homeostasis that has not been found in developing or diseased valves [79]. Further
studies are necessary to determine if ATF4 or Osx gene expression is induced or if they con‐
tribute to valve mineralization in CAVD.
3.3. Signaling pathways involved in bone development
Multiple signaling pathways control the stages of bone cell lineage determination, differen‐
tiation and maturation [80, 107]. These include BMP, Wnt, and Notch pathways, also active
in developing and diseased heart valves, as well as FGF, hedgehog, insulin-like growth fac‐
tor (IGF), and retinoic acid (RA) pathways, not yet characterized in heart valve pathogenesis
[80]. BMP, Wnt, and Notch pathways are required at multiple stages of osteogenesis and
have distinct regulatory interactions that control transcription factor function and cell type-
specific gene expression in cartilage and bone cell lineages (Figure 2). In addition, these
pathways crosstalk with each other in synergistic and antagonistic regulatory interactions.
Strikingly many of these same regulatory interactions occur in heart valve development and
pathogenesis (Table 1) [8].
Bone morphogenetic proteins were originally identified based on their ability to induce ec‐
topic bone formation [108]; however, in vivo functions in normal bone development are less
clear [109]. In the developing limb buds, BMP signaling has a critical role in mesenchymal
condensation, Sox9 activation, and cartilage lineage differentiation [89]. Thus BMP signaling
is an important regulator of the earliest stages of skeletal development. Later in differentiat‐
ing osteoblasts, BMP signaling through Smad1/5/8 phosphorylation (pSmad1/5/8) promotes
osteogenic differentiation and calcification [110]. Runx2 directly binds to activated Smads1
and 5 to cooperatively activate osteoblast gene expression in response to BMP signaling
[109]. Conditional loss of BMP2 and BMP4 in the osteoblast lineage in mice inhibits late
stage differentiation into Osx1-positive osteocytes, and BMP signaling is required for bone
homeostasis after birth [80, 109]. Surprisingly, earlier stages of bone lineage development
are apparently unaffected with conditional loss of these ligands.
Wnt/β-catenin signaling is required for osteoblast differentiation as demonstrated by loss of
osteoblast differentiation with conditional loss of β-catenin in osteochondroprogenitor cells
in mice [80]. In addition, loss of β-catenin in pre-osteoblasts leads to ectopic cartilage forma‐
tion, thus implicating Wnt signaling in osteogenic versus chondrogenic cell fate determina‐
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tion. At a molecular level, Wnt/β-catenin signaling promotes osteoblast lineage
differentiation, while inhibiting chondrogenesis, by activating Runx2, while inhibiting Sox9
[77]. In bone lineages, BMP and Wnt signaling act synergistically to promote calcification,
although neither pathway alone is sufficient to induce a full osteogenic response [111]. Dur‐
ing the initial differentiation of bone progenitor cells, regulatory elements of Runx2 and
Msx2 genes are bound by Smad1, downstream of BMP signaling, and also by Lef1, activated
by Wnt signaling, for cooperative gene activation [112]. Postnatally, Wnt signaling through
the Lrp5 receptor is required for bone accrual in mice and humans [80]. In developing bone,
osteogenic differentiation and calcification are dependent on sequential activation of BMP,
followed by Wnt/β-catenin, signaling [110]. It is possible that a similar regulatory relation‐
ship exists in CAVD, but this has not yet been demonstrated.
Notch activation inhibits osteogenesis through suppression of the Wnt/β-catenin pathway
and Runx2 transcription factor activity [94, 113, 114]. Loss of Notch1 or Notch2 function pro‐
motes osteoblast differentiation and leads to increased bone mass in mice [115]. Notch path‐
way activation inhibits the progression of osteoblast differentiation through direct binding
of the activated Notch1 intracellular domain (N1ICD) to β-catenin, thereby counteracting
Wnt-mediated induction of osteogenesis [113, 114]. In addition, the Notch target gene Hey1
encodes a transcriptional repressor that binds and inhibits Runx2 transcriptional function
[115]. Precise levels of Notch signaling are required for cell proliferation and chondrogenic
differentiation, with defects in these processes occurring with increased or decreased Notch
signaling in mice [116]. In early cartilage precursors, Notch signaling is required for cell pro‐
liferation, but increased Notch signaling inhibits terminal differentiation of chondrocytes
and endochondral ossification [116]. Loss of Notch signaling has been implicated in CAVD
[64], but it is not known if this occurs through inhibition of Wnt/β-catenin signaling, as has
been demonstrated for osteoblast differentiation and bone mineralization.
4. Molecular and cellular mechanisms of CAVD
4.1. Overview of CAVD progression
The mature aortic valves are comprised of three ECM layers critical for normal leaflet struc‐
ture and function [24, 44, 117]. Collagen predominates in the fibrosa layer, which is oriented
on the opposite side of blood flow, whereas elastin is enriched in the ventricularis layer on
the flow side of the valve. Between the fibrosa and ventricularis layers, is the proteoglycan-
rich spongiosa layer [24, 44, 117]. This trilaminar ECM arrangement is preserved among spe‐
cies, and lends both strength and elasticity to the aortic valves [24]. In CAVD, the aortic
valve becomes thickened and displays extensive ECM remodeling and mineralization
[118-121]. Abnormal thickening (aortic valve sclerosis) and calcification of the aortic valve
lead to stiffening of the valve leaflets and can reduce the effective valve opening (aortic
valve stenosis), which can impede blood flow and lead to clinical symptoms such as syn‐
cope and angina [119, 122, 123]. Histologically, human explanted diseased aortic valves have
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extensive ECM remodeling and elastic fiber fragmentation with evidence of both macro‐
scopic calcific nodule formation as well as microscopic mineral deposits [119].
Changes in the resident VICs are apparent in CAVD. Under normal conditions, aortic VICs
are quiescent and non-proliferative [13, 24, 104, 124]. However, in disease, a subset of aortic
VICs exhibits features of myofibroblast activation, which is characterized by expression of
α-smooth muscle actin (αSMA), MMP13, non-muscle myosin heavy chain (SMemb), and
markers of proliferation [13, 104, 119, 124, 125]. In vivo, the factors responsible for inducing
myofibroblast activation are not well defined. However, in culture, TGFβ1 stimulation and
mechanical strain are potent inducers of VIC myofibroblast activation [125, 126]. Activated
VICs also exhibit characteristics of valve and bone precursor cells as they induce expression
of the common mesenchymal markers Sox9, Twist1, and Msx2 [13]. Currently it is unknown
where the mesenchymal-like cells come from and what role these proliferative cells play in
the progression of CAVD pathogenesis.
Valve calcification, apparent as hydroxyapatite deposits on the surface of or within the leaf‐
lets, is a prominent feature of CAVD [119, 127, 128]. Histologically, valve calcific nodules are
primarily acellular [13, 129]. Although traditionally thought to be a completely passive dep‐
osition of mineral, in some cases, valve calcification is coincident with endochondral bone-
like and cartilaginous-like nodules [129, 130]. Aortic valve calcification is observed primarily
in the regions of the valves exposed to the greatest physical strain, specifically at the hinge
region of the valve and along the line of leaflet coaptation [120]. Furthermore, calcification is
predominantly found in the fibrosa layer of the diseased valve, which is similar to early
bone matrix as it is contains primarily fibrillar collagen [44]. Expression of other bone matrix
molecules, such as osteocalcin and osteopontin, are induced during disease [5]. Further‐
more, expression of osteogenic factors, such as Runx2, BMP2, and alkaline phosphatase, also
is induced in VICs from calcified valves, suggesting that resident VICs may have the poten‐
tial to undergo osteogenic transdifferentiation and actively contribute to valve calcification
(reviewed in [131]).
Extrinsic factors have been implicated in valve calcification. For example, lipid deposition
and immune cell infiltration are common histopathological features of CAVD, and it has
been proposed that aortic valve calcification occurs by mechanisms similar to arterial calci‐
fication in atherosclerosis [119, 132-135]. In addition, altered external physical forces elicit
changes  in  resident  VICs,  which  play  an  active  role  in  pathological  valve  calcification
[126]. In contrast to VIC response to immune cell infiltration and altered physical forces,
cell  intrinsic  mechanisms may also  contribute  to  valve  calcification,  as  stimulation with
factors such as BMP2 or TGFβ1 in cell culture studies can induce VIC calcification in the
absence  of  inflammatory  stimulation  or  altered  physical  forces  [126,  136-138].  Together,
these studies suggest that not only is valve calcification an active cell-regulated process,
but that many factors likely contribute to progression of calcification during disease. It is
also likely that not all  CAVD is created equal.  Genetic predisposition, the presence of a
malformed aortic valve, and other disease comorbidities, such as coronary artery disease,
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hypertension,  and  kidney  disease,  likely  affect  the  pathology  and  underlying  cause  of
CAVD [64, 139-142].
4.2. Activation of progenitor cell and osteogenesis-related molecular pathways in CAVD
4.2.1. Expression of valve and bone progenitor cell genes in CAVD
The mesenchymal markers Twist1, Msx2, and Sox9 are expressed in adult calcific aortic
valves in mesenchymal-like activated VICs [12, 13, 106, 143, 144]. As discussed, these genes
are expressed in both valve and bone mesenchymal progenitor cells. A recent study has
compared gene expression in pediatric versus adult aortic valve disease and shown that the
mesenchymal markers Twist1, Msx2, and Sox9 are increased in both [13]. The observation
that both pediatric and adult diseased valves have increased expression of the mesenchymal
markers suggests that this expression is related to VIC activation and proliferation, which is
common to both, and not related to valve calcification, which is found only in advanced
adult disease [13]. In both valve and bone progenitors, Twist1, Msx2, and Sox9 induce pro‐
liferation and promote a mesenchymal phenotype, thus reactivation in diseased valves is
suggestive of a similar role in valve pathogenesis [38, 40-42, 84, 88, 145]. Although it is pre‐
sumed that resident VICs re-activate these early mesenchymal markers, other possibilities
exist. EMT as a mechanism for VIC activation has not been established in CAVD, however,
recent studies report EMT-like events in adult valves. Increased cyclic strain and altered he‐
modynamics, both recognized features of CAVD, can induce EMT in isolated sheep valve
endothelial cells [146, 147]. In addition, cultured valve endothelial cells stimulated with
TGFβ adapt a mesenchymal-like phenotype and express markers of both endothelial and
mesenchymal cells, suggesting that they can undergo EMT [148, 149]. Likewise, disruption
of Notch signaling in adult mice induces aortic valve thickening with evidence of endocar‐
dial EMT, as indicated by endocardial cells with more pseudopodial projections, loose endo‐
cardial cell-cell junctions, and αSMA expression [150]. Additional sources of mesenchymal-
like cells have been suggested. For example, circulating bone marrow-derived
hematopoietic stem cells have been shown to integrate into the valve interstitium, adapt fi‐
broblast-like characteristics, and surround regions of prominent valve calcification in hu‐
man end stage CAVD [33, 130, 151]. It is uncertain what role reactivation of the
mesenchymal markers Twist1, Msx2, and Sox9 have in potential valve repair mechanisms or
in the progression of CAVD. It is possible that adult VICs maintain a certain “mesenchymal-
plasticity” and are able to revert back to an early progenitor-like mesenchymal cell during
disease. Alternatively, they may be indicators of newly derived VICs arising from EMT or
circulating progenitor cell populations in response to disease conditions.
4.2.2. Osteogenic factors in CAVD
Molecular mechanisms of endochondral ossification and cartilaginous nodule formation are
active in CAVD [7, 13]. Studies in human explanted diseased aortic valve tissues have dem‐
onstrated increased expression of the osteogenic factors BMP2, TGFβ1, Runx2, osteocalcin
(OCN), osteopontin (OPN), osteoprotegerin (OPG), bone sialoprotein (BSP), alkaline phos‐
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phatase (ALP), and Osx in disease [5, 13, 106, 118, 137, 152]. At a molecular level, BMP2 sig‐
naling is a key inducer of VIC calcification, which is thought to act through p-SMAD1/5/8
and phospho-ERK1/2 signaling to stimulate increases in both Runx2 and OPN expression
[138]. Induction of VIC calcification by BMP2 stimulation is highly reminiscent of BMP sig‐
naling in bone development, suggesting that some parallels exist between osteogenic bone
formation and VIC calcification [9]. Histological studies of explanted human valves further
support a role for BMP signaling in valve calcification. Comparison of pediatric diseased
valves, which do not acquire calcification, and adult calcified valves demonstrates that in‐
creased BMP signaling, evident in p-SMAD1/5/8 activation, is exclusive to adult valves with
calcification, indicating that BMP signaling may contribute to valve calcification in human
disease [13]. Additionally, TGFβ1 is also a potent inducer of osteogenic-like differentiation
of VICs in cell culture, as it stimulates VIC activation and calcification, increases ALP activi‐
ty, and increases expression of ECM remodeling enzymes [126, 136, 137]. Negative regula‐
tors of valve calcification have been demonstrated through in vivo studies. One negative
regulator of valve calcification is Notch signaling. Animals haploinsufficient for Notch sig‐
naling develop aortic valve calcification with increased BMP signaling and increased expres‐
sion of Runx2 in the valve leaflets [65, 153]. Studies in isolated aortic VICs further
demonstrate that Notch signaling plays an important role in suppressing valve calcification
as treatment of VICs with Notch inhibitors induces BMP signaling and subsequent increases
in osteogenic gene expression [65, 153]. Another negative regulator of valve calcification is
Sox9, which potentially acts through induction of proteoglycan expression, similar to what
has been observed in developing cartilage [40, 49]. Conditional heterozygous Sox9 mutant
mice develop valve calcification along with increased valve thickness and expression of the
osteogenic genes Runx2, osteonectin, OPN, and OPG [40, 49]. Based on these studies, it is ap‐
parent that many factors involved in endochondral bone formation are active in the process
of aortic valve calcification.
CAVD has been linked to chronic kidney disease in human patients and animal models [140,
154-157]. A prominent pathological feature of kidney disease is the inability to regulate cal‐
cium and phosphate metabolism [158]. Increased blood phosphate levels (hyperphosphate‐
mia) are highly associated with aortic valve sclerosis and valve calcification in humans [140].
Klotho-null mice are a model of accelerated aging that includes development of kidney fail‐
ure and hyperphosphatemia, along with cardiovascular disease [159-162]. Klotho-null mice
exhibit extensive valve annulus calcification with increased expression of osteogenic genes,
but minimal CD68 positive macrophage infiltration [73]. Thus, valve calcification in the klo‐
tho-null animals parallels bone formation, where increases in crucial osteogenic genes, such
as Col10a1, Runx2, OPN, and BSP, are observed [73]. These observations suggest that in‐
creased blood phosphate levels could be one stimulus for inducing advanced aortic valve
calcification with osteogenic gene expression, but this has not been definitively demonstrat‐
ed [73, 140].
Atherogenic lipid deposition and inflammation in the valves also has been linked to induc‐
tion of osteogenic gene expression and disease [163-165]. Rabbit and mouse models of
CAVD, induced with hypercholesterolemic or high fat diets, have increased lipid deposition
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and macrophage infiltration associated with induction of osteogenic markers such as ALP,
OCN, OPN, Runx2, and Osx [165-167]. Although osteogenic gene expression is induced in
these models, this type of valve calcification closely mimics vascular calcification observed
in atherosclerosis, rather than endochondral bone formation, due to the presence of exten‐
sive immune cell infiltration [165, 166]. In support, human aortic VICs stimulated with pro-
inflammatory mimetics not only induce the expression of inflammatory cytokines, but also
induce the expression of osteogenic factors, such as BMP2 and Runx2, again suggesting that
this process may be similar to what is occurring in atherosclerotic disease [164, 168]. Based
on this evidence, multiple physiologic factors likely contribute to osteogenic gene induction
in calcified diseased aortic valves.
4.2.3. Valvulogenic- and osteogenic-related signaling pathways in CAVD
As in both heart valve and endochondral bone development, BMP, TGFβ, Notch, and Wnt
signaling have been implicated in the progression of CAVD (Figure 2; Table 1). Increased
BMP ligand expression, particularly BMP2 and BMP4, has been demonstrated histologically
in human explanted calcific aortic valves surrounding and throughout regions of valvular
calcification [118, 129]. Furthermore, active BMP signaling, as indicated by pSMAD1/5/8 ex‐
pression, is present in both human explanted diseased aortic valves and animal models of
CAVD [13, 169, 170]. Comparison of pediatric diseased valves void of calcification to heavily
calcified adult diseased valves demonstrates extensive ECM remodeling and evidence of
VIC activation in both; however, increased pSMAD1/5/8 signaling is exclusive to calcified
valves [13]. The observation that pSMAD1/5/8 expression is found only in adult calcified
valves is suggestive of a critical role for BMP signaling as an initiating osteogenic factor in
CAVD [13]. Furthermore, increased pSMAD1/5/8 expression reportedly localizes to the fi‐
brosa layer of human calcific aortic valves, which is the primary sight of aortic valve calcifi‐
cation [169]. Cell culture studies support this and show that BMP2 stimulation promotes
osteogenic-like aortic valve calcification in human aortic VICs by inducing the expression of
the osteogenic factors Runx2, OPN, and ALP [138, 171]. Based on this evidence, active BMP
signaling may be a potential therapeutic target to treat CAVD, however it has not yet been
tested.
TGFβ signaling induces α SMA expression and myofibroblast differentiation of porcine
aortic VICs, suggesting that TGFβ promotes VIC activation, potentially in response to physi‐
cal strain [125, 172]. Furthermore, TGFβ signaling may also have a role in aortic valve calcifi‐
cation, as human explanted calcific aortic valves have increased levels of TGFβ1 expression
and ovine aortic VICs in culture calcify in response to TGFβ1 induction [136, 137]. TGFβ sig‐
naling has also been linked to both Wnt/β-catenin and FGF signaling pathways in CAVD
[173, 174]. Specifically, FGF signals have been shown to induce MAPK signaling, which in‐
hibits aortic VIC αSMA expression and myofibroblast response to TGFβ [174]. In addition,
TGFβ stimulation of aortic VICs induces nuclear localization and activation of β-catenin,
which promotes VIC myofibroblast differentiation [173]. Although the role of TGFβ in
CAVD is not well established in vivo, there is accumulating evidence for a role in VIC acti‐
vation and calcification from studies in cell culture systems.
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Whereas both BMP and TGFβ signaling have been found to induce VIC calcification, Notch
signaling has been implicated as a negative regulator of valve calcification. Familial studies
demonstrated that Notch1 haploinsufficiency is associated with CAVD and aortic stenosis
(AS) [64]. During development, Notch1 is expressed in the endothelial cells lining the aortic
valve cusps and is also observed at lower levels in the VICs, and this expression pattern is
maintained into adulthood [64, 175]. Histological analysis of human explanted aortic valves
demonstrates that activated Notch1 intracellular domain (NICD) expression is dramatically
reduced in VICs directly adjacent to regions of aortic valve calcification [175]. This observa‐
tion is consistent with a mechanism whereby Notch signaling inhibits valve calcification and
downregulation of Notch expression promotes valve calcification [175]. The idea that Notch
signaling functions as a negative regulator of calcification was originally defined in endo‐
chondral bone formation, where downstream effectors of Notch signaling, Hes1 and Hey1,
repress Runx2 transcriptional function, leading to expansion of hypertrophic cartilage and
impaired osteoblast differentiation [115]. Notch1 heterozygous or RBPJ heterozygous mice
develop CAVD, as evidenced by increased aortic valve calcification, and also display signifi‐
cant increases in BMP/pSMAD1/5/8 signaling and Runx2 expression in the aortic valves [65,
153]. Likewise, deletion of RBPJ in adult mice results in increased aortic valve thickness with
evidence of VIC proliferation and potentially, endothelial EMT [150]. Together these in vivo
studies support the idea that Notch signaling represses BMP expression, thereby indirectly
repressing other osteogenic factors [65, 153]. Cell culture studies indicate that Notch inhibi‐
tion promotes calcification of VICs by repressing chondrogenic genes, including Sox9, and
inducing expression of the osteogenic genes OPN, osteonectin, Runx2, ALP, and BMP2 [65,
153, 175]. Specifically, Notch signaling in the aortic valves is thought to induce expression of
Sox9, which is a negative regulator of calcification, and to repress the expression of both
Runx2 and BMP2, which are known to stimulate osteogenic differentiation [64, 153, 175].
These studies suggest that, in the absence of a negative regulator of calcification, the resident
VICs possess an intrinsic calcification mechanism, which becomes activated and subse‐
quently induces valve calcification. Combined, the evidence suggests that Notch signaling is
a negative regulator of VIC osteogenic differentiation, and that the absence or dysregulation
of Notch signaling can induce valvular calcification.
Wnt/β-catenin signaling is important for osteoblast maturation during embryonic develop‐
ment and contributes to mineralized bone formation (reviewed in [80]). A number of studies
have also shown activation of Wnt/β-catenin signaling in aortic valve calcification. Canoni‐
cal Wnt signaling acts through the frizzled receptors and the Wnt co-receptors Lrp5 and
Lrp6, resulting in β-catenin nuclear localization and TCF/LEF1 activation [176]. Human ex‐
planted calcific AoVs have increased expression of Lrp5, β-catenin, and Wnt3a ligand as
compared to control valves [143]. Increased Wnt signaling in diseased aortic valves also has
been observed in multiple animal models of CAVD. Pigs and rabbits maintained on an athe‐
rogenic diet develop aortic valve disease and display increased expression levels of β-cate‐
nin and Lrp5 receptor [173, 177]. Likewise, in a subset of endothelial nitric oxide synthase
(eNOS) deficient mice that develop BAV, expression of Wnt3a ligand and Lrp5 receptor is
increased when the animals are fed a high cholesterol diet [178]. Cell culture studies also
support the idea that Wnt/β-catenin signaling is important for VIC myofibroblast activation,
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proliferation, and chondrogenic gene induction. Studies in porcine aortic VICs show that
Wnt3a treatment induces significant VIC proliferation and myofibroblast activation [173,
179]. Furthermore, Wnt3a treatment of embryonic chicken aortic VICs results in increased
expression of periostin and mgp, but does not induce the expression of osteogenic-related
genes, suggesting that Wnt3a signaling is not sufficient for VIC osteogenic differentiation
[60]. However in adult valves, Wnt signaling can promote the VIC calcification response, as
loss of Wnt signaling through the Lrp5 receptor in ApoE knockout mice results in decreased
aortic valve calcification [180]. Together these studies demonstrate that Wnt signaling likely
contributes to VIC activation, proliferation, and calcification in CAVD.
4.3. Matrix remodeling in CAVD
Diseased aortic valves are characterized by changes in the ECM; in particular, disorganized
collagen bundles and extensive elastic fiber fragmentation are observed [181, 182]. Insight
into the role of elastin fiber disorganization in the pathogenesis of CAVD has been provided
through studies of elastin haploinsufficient mice, which display elastin fiber fragmentation,
abnormal ECM remodeling, and increased valve stiffness, suggesting that elastin homeosta‐
sis is important for maintaining valve function [72, 183]. Collagen synthesis and remodeling
are dramatically increased in CAVD, however, overall collagen content in the valve is ac‐
tually decreased, suggesting that there is extensive collagen proteolysis during disease
[184-186]. In contrast to collagens, expression of proteoglycans, including decorin, biglycan,
versican, and hyaluronan, is increased particularly in regions of the diseased valve adjacent
to calcific nodules [187]. These changes in ECM composition during CAVD can be compared
to matrix remodeling events that occur during valve development and also in bone forma‐
tion. The decreased collagen content and increased proteoglycan matrix found in CAVD is
similar to the primitive ECM characteristic of early valve development [188]. Furthermore,
parallels can also be drawn between matrix remodeling in CAVD and bone development.
Specifically, matrix remodeling in the immature bone is essential for providing a scaffold
upon which the calcified matrix is deposited, and subsequent ECM degradation is essential
for expansion of the calcified regions of newly forming bone [189]. The parallels between
matrix remodeling in bone development and the disease process of CAVD suggest that
valve matrix remodeling may contribute to valvular calcification.
Matrix degradation and remodeling in valvulogenesis, osteogenesis, and CAVD occurs con‐
comitant with increased activity of MMPs and cathepsins, along with increased RANKL sig‐
naling. A number of studies have shown significant increases in expression of multiple
MMPs, including MMP1, MMP3, MMP7, MMP9, and MMP12, with increased cathepsins B,
K, and S in human calcific diseased aortic valves, suggesting that extensive ECM remodel‐
ing is a key feature of disease [124, 163, 181, 182, 184, 190]. In bone, RANKL signals through
the RANK receptor, which can be inhibited via binding to the soluble receptor OPG, and
promotes the expression of proteolytic enzymes, such as MMPs and cathepsin K, through
activation of NFATc1 [191, 192]. A similar mechanism has been identified in heart valve re‐
modeling [47, 61]. Comparison of sclerotic diseased aortic valves and advanced stenotic
aortic valves determined that OPG levels are significantly higher in sclerotic valves without
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calcification, whereas RANKL expression is higher in stenotic calcified valves [103, 193].
This study concluded that OPG may be protective against valve calcification, whereas ele‐
vated RANKL expression may promote valve calcification by promoting upregulation of
matrix remodeling enzymes [103, 193]. Furthermore, treatment of human aortic VICs with
RANKL results in increased MMP1 and MMP2 activity with increased VIC proliferation,
concomitant with increased calcification and osteogenic gene expression [103, 191]. In addi‐
tion, NFATc1 expression is increased in human explanted aortic valve leaflets with CAVD
[106]. Together, these studies are consistent with signaling events during bone development,
namely RANKL activation of NFATc1, stimulating matrix remodeling enzymes, and pro‐
moting calcification [192].
A number of other signaling pathways are likely involved in ECM changes that occur dur‐
ing CAVD. In particular, TGFβ1 stimulation of cultured VICs stimulates myofibroblast dif‐
ferentiation, leading to increased levels of αSMA stress fibers in the VICs [125, 172]. It has
been suggested that these myofibroblasts then exert a contractile force on the surrounding
valve ECM and stimulate rearrangement of the matrix, particularly in fibronectin fibers
[125]. Furthermore, TGFβ1 stimulation also induces increased type I collagen production
and expression of the matrix remodeling enzymes MMP9 and MMP2 in cultured aortic VICs
[136, 172]. These studies indicate that TGFβ1 signaling may be a key factor in ECM-related
changes during CAVD pathogenesis. Moreover, Wnt signaling may work in concert with
TGFβ1 to induce changes in ECM during CAVD [173]. TGFβ1 stimulation promotes nuclear
localization and activation of β-catenin in cultured VICs, and, when combined, Wnt and
TGFβ1 signaling dramatically increases myofibroblast activation [173]. In contrast to TGFβ1
and Wnt signaling, FGF signaling may work to inhibit ECM remodeling during valve dis‐
ease. FGF signaling has been shown to block TGFβ1 induced myofibroblast differentiation
and αSMA expression in porcine aortic VICs through activation of phospho-ERK1/2 signal‐
ing [174]. In addition, FGF signaling inhibits myofibroblast contraction of a collagen matrix,
supporting the idea that FGF signaling blocks TGFβ1 stimulation of matrix-related changes
[174]. Many parallels exist between signaling factors involved in ECM changes in develop‐
ment and disease. In particular, RANKL, TGFβ1, Wnt, and FGF signaling have demonstrat‐
ed roles in ECM production and regulation in both heart valve and endochondral bone
formation [8, 76]. The shared signaling pathways in these tissues, both in development and
disease, suggest that developmental pathways may be reactivated in CAVD to induce ma‐
trix changes characteristic of the disease.
5. Therapeutic mechanisms in CAVD
Currently, aortic valve replacement surgery is the only effective treatment option for CAVD
[122]. There have been numerous studies, which are summarized below, testing the effec‐
tiveness of different pharmacotherapies on preventing the progression of AS. Unfortunately,
studies on statin therapies, inhibitors of the renin-angiotensin-aldosterone system, and os‐
teoporosis treatments have not been proven to be effective at preventing the symptoms or
the progression of CAVD/AS. Following the summary of these studies, additional treatment
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options, related to the expression of developmental and osteogenic-related genes in CAVD,
are discussed.
5.1. Statins
Lipid deposition and the accumulation of apolipoproteins (Apo) in the aortic valve leaflets
have long been associated with CAVD, and many studies have compared the progression of
CAVD to atherosclerotic disease [119, 133, 134, 194]. Therefore, it has been hypothesized that
cholesterol lowering therapy with statin drugs may be an effective treatment strategy to de‐
lay the progression of CAVD. A specialized mouse model called “Reversa” mice develop
signs of CAVD when fed a high cholesterol diet, however, when serum cholesterol is low‐
ered via a genetic deletion of the microsomal triglyceride transfer protein (Mttp), reduced
levels of aortic valve calcification, as well as decreased expression of the osteogenic markers
pSMAD1/5/8, Msx2, Osx, β-catenin, and Runx2, are observed [167, 170]. Thus reducing plas‐
ma cholesterol may reduce CAVD pathogenesis, particularly in terms of reducing osteogen‐
ic gene expression in the diseased valves. Similarly, statin treatment of human or porcine
aortic VICs cultured concomitantly with osteogenic media results in decreased expression of
the osteogenic genes ALP, OCN, Lrp5, and OPN, and reduced calcific nodule formation
[171, 177, 195]. However, when statin treatment of aortic VICs is initiated after osteogenic
transformation or calcific nodule formation, it is ineffective at reducing calcification and ex‐
pression of osteogenic markers, indicating that statin therapy cannot reverse aortic valve cal‐
cification and osteogenic differentiation once it has occurred [195, 196]. Results from animal
studies are equally contradictory. Rabbits fed a high cholesterol diet supplemented with
atorvastatin have decreased aortic valve thickness, reduced VIC proliferation, and reduced
expression of Lrp5, β -catenin, OPN, Runx2, and ALP, compared to those animals fed only a
high cholesterol diet [165, 177]. Similarly, endothelial nitric oxide synthase (eNOS) deficient
mice, displaying a BAV phenotype and fed a high cholesterol diet, have reduced Lrp5 and
Wnt3a expression as well as reduced aortic valve calcification when treated with statins,
compared to animals fed only a high cholesterol diet [178]. In contrast, a long term study in
rabbits fed a high cholesterol diet showed that atorvastatin therapy initiated after aortic
valve disease is established is not effective at reducing the amount of aortic valve calcifica‐
tion present, although some improvements in other histological parameters were noted
[197]. Based on both cell culture and animal studies, statin therapy may improve some
measures of aortic valve calcification, specifically in terms of reducing osteogenic gene ex‐
pression, however, firm conclusions as to potential efficacy as a CAVD treatment cannot be
drawn.
Clinicial studies investigating the use of statin therapy in patients with CAVD are also wide‐
ly contradictory. An early study investigating the use of statin therapy in patients with mod‐
erate to severe aortic stenosis (AS) reported that patients treated with statins had less
hemodynamic progression of AS over a 2 year time period than patients who were not on
statin therapy [198]. In contrast, three larger prospective clinical studies, SALTIRE (Scottish
Aortic Stenosis and Lipid Lowering Trial, Impact on Regression), SEAS (Simvastatin and
Ezetimibe in Aortic Stenosis), and ASTRONOMER (Aortic Stenosis Progression Observa‐
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tion: Measuring Effects of Rosuvastatin), found that statin therapy was not effective at treat‐
ing the progression of AS [199-201]. In these trials, three different statin therapies were
investigated in patients with mild to moderate AS and it was determined that statin therapy
did not alter the progression of CAVD/AS nor prevent outcomes such as the necessity to un‐
dergo aortic valve replacement surgery [199-201]. In response to the negative outcomes of
these large clinical trials, the use of statin therapy was next investigated in patients with the
earliest form of CAVD/AS, aortic valve sclerosis, to determine if statin use could prevent,
rather than reverse, AS [202]. In this report, statin therapy was significantly associated with
a decreased development of AS and a decreased need for aortic valve replacement surgery,
suggesting that statin therapy may be an effective treatment if started at the earliest stages of
the disease, prior to any indication of valve calcification [202]. Based on these studies, it can
be concluded that in humans, statin therapy is ineffective at preventing the progression of
AS and reversing aortic valve calcification. However, statin therapy may be useful at pre‐
venting the onset of AS in patients with the earliest stages of aortic valve thickening.
5.2. Angiotensin converting enzyme inhibitors/Angiotensin receptor blockers
Another potential therapy to prevent the progression of CAVD/AS is the use of the anti-hy‐
pertensive angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor
blockers (ARB). Currently, ACEIs and ARBs are prescribed to treat hypertension, and func‐
tion by acting on the renin-angiotensin-aldosterone system to ultimately inhibit the vasocon‐
strictor effects of angiotensin II [203]. Previous reports have identified the overlapping
expression of angiotensin-converting enzyme (ACE) and angiotensin II in calcified human
aortic valves surrounding regions of valvular calcification [133]. It has been hypothesized
that ACE inhibition may prevent the progression of CAVD by reducing ACE activity in the
diseased valve leaflet [204-206]. A study conducted in ApoE knockout mice with induced
chronic renal failure concluded that animals treated with the ACEI enalapril had significant‐
ly reduced levels of pathologic aortic valve leaflet thickening and valve fibrosis than un‐
treated animals [206]. Similarly, in a rabbit model of CAVD in which the animals were fed a
high vitamin D diet, treatment with the ACEI ramipril significantly reduced the progression
to AS, improved valve endothelial cell integrity, and reduced aortic valve calcification [205].
It is uncertain how ACE and angiotensin receptor (AR) inhibition would directly affect mo‐
lecular changes in the valve leaflets. However, in a study of rabbits fed a high cholesterol
diet, treatment with the ARB olmesartan decreased the number of α SMA positive myofibro‐
blasts and reduced expression of the osteogenic markers Runx2 and OPN, compared to un‐
treated control animals [204]. These animal studies suggest that ACE and/or AR inhibition
may reduce pathologic changes in aortic valve disease by limiting valve fibrosis, reducing
myofibroblast activation, and decreasing osteogenic gene expression.
Clinical studies testing the therapeutic benefits of ACEIs and ARBs in CAVD progression
have had mixed results. In human explanted aortic valve tissues, ARB therapy is associated
with reduced aortic valve remodeling and calcification [207]. As in animal studies, this his‐
tological analysis suggests that AR inhibition may limit aortic valve calcification [207]. In a
small pilot clinical study (Symptomatic Cardiac Obstruction – Pilot Study of Enalapril in
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Aortic Stenosis), use of the ACEI Enalapril was associated with improved clinical symptoms
in patients with severe symptomatic AS [208]. The majority of studies investigating the use
of ACEIs or ARBs in CAVD/AS with positive outcomes have been retrospective. In three dif‐
ferent retrospective studies, ACEI or ARB use in patients with mild to moderate AS was as‐
sociated with decreased mortality, decreased number of adverse cardiovascular events,
slower progression of AS, and less accumulation of valvular calcification [209-211]. Addi‐
tionally, one prospective study followed a small random population of patients over a 4-
year period and reported that the use of ACEIs or ARBs was significantly associated with
reduced CAVD/AS disease progression [212]. Together, these studies provide evidence that
ACEI and ARB may delay CAVD progression. Conversely, there have also been a number of
studies that show no association between ACEI and ARB use and improved outcomes in
CAVD progression. The JASS study (Japanese Aortic Stenosis Study) reported that ARB
therapy in patients with moderate to severe AS had no beneficial outcomes in CAVD pro‐
gression, although patients with mild asymptomatic AS had some indication of reduced
progression to AS [213]. Furthermore, a large study in patients with very mild asymptomat‐
ic AS found that patients on ACEI or ARB therapy had no improvement in the progression
of AS compared against a control group [202]. Similarly, a small 2-year study observed no
difference in the hemodynamic progression of AS with ACEI use versus non-use [198].
Based on both animal and clinical studies, it is unclear whether ACEI or ARB therapy is an
effective treatment option to prevent the progression of CAVD/AS, however there are indi‐
cations that perhaps this therapy may limit valve calcification [204, 207]. A placebo control‐
led, blinded trial will be necessary to determine the effectiveness of these therapies in
treating CAVD.
5.3. Aldosterone-receptor antagonists
Aldosterone is a component of the renin-angiotensin-aldosterone system that plays a key
role in the kidney to regulate water and sodium reabsorption and effectively raise blood
pressure [203]. Aldosterone-receptor antagonists (ARA) are commonly prescribed for their
diuretic effects [203]. Recently, there have been two studies investigating the use of ARAs in
the treatment of CAVD/AS. In an animal study, rabbits fed a high cholesterol diet develop
aortic valve sclerosis, with thickening of the valve leaflets and microscopic calcific deposits,
which was blocked by treatment with the ARA eplerenone [214]. In addition to reducing
valve fibrosis and mineralization, evidence of macrophage infiltration was also reduced
[214]. Conversely, in a small placebo-controlled human trial of patients with moderate to se‐
vere asymptomatic AS, there was no difference in the progression of AS in those patients
receiving the ARA eplerenone versus placebo [215]. To our knowledge, no molecular evi‐
dence has been reported in studies on ARA therapy in CAVD and it is unknown whether
ARA therapy affects myofibroblast activation or osteogenic gene induction. Additional clini‐
cal studies will be necessary to determine if ARA use can prevent AS progression if therapy
is started in early disease stages.
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5.4. Bisphosphonates
Bisphosphonates (BP) are a class of drugs that mimic inorganic pyrophosphate and prevent
ectopic soft tissue calcification and inhibit bone resorption [216]. In adults, especially wom‐
en, BPs are commonly prescribed to treat excessive bone resorption associated with osteopo‐
rosis [216]. Human aortic VICs, grown on collagen gels in the presence of a specialized thiol
bisphosphonate, have decreased ALP activity and reduced cellular aggregation, a step that
precedes calcific nodule formation, as compared to cells grown on collagen alone [217]. This
study suggests that bisphosphonates may inhibit VIC calcification in vitro and could serve
as a potential therapeutic strategy to prevent aortic valve calcification [217]. Due to the abili‐
ty of BPs to prevent ectopic calcification in bone and the availability of patient populations
currently using BPs, a number of studies have investigated the use of BPs in the inhibition of
aortic valve calcification. Three small retrospective human studies compared measurements
of AS progression over a 2-year period in patients with AS taking BPs versus those not tak‐
ing BPs [218-220]. The results of these studies suggest a modest reduction in the progression
of AS in those patients taking BPs [218-220]. The large MESA study (Multi-Ethnic Study of
Atherosclerosis) followed women taking BPs, compared to those not taking BPs, and their
development of CAVD/AS over time [221]. The results of this study were mixed and
showed that, in older women, BP therapy was associated with a slight benefit in terms of
aortic valve calcification, whereas, younger women taking BPs had significantly more pro‐
gression of aortic valve calcification compared to women not taking BPs [221]. Most recent‐
ly, a large retrospective study investigated the progression of AS in women with mild to
moderate AS over a 5-year period and compared the outcomes in patients on BP therapy
versus those not taking BPs [222]. The evidence from this study shows that there was no
change in survival, or in the number of aortic valve replacement surgeries, in women taking
BPs compared to those not taking BPs, suggesting that BP therapy does not suppress the
progression of CAVD/AS [222]. Thus far, the outcomes of the human studies investigating
the use of bisphosphonate therapy in CAVD demonstrate that this therapy is ineffective at
preventing or delaying the progression of CAVD/AS. To definitively determine whether or
not BP therapy is effective at suppressing the progression of CAVD/AS, placebo-controlled
prospective studies will be necessary.
5.5. Nitric oxide bioavailability
Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO) from L-arginine, and
eNOS expression has been identified in the endothelial cells lining the aortic valves [68].
eNOS deficiency has been linked to defective aortic valve development, as approximately
50% of eNOS deficient mice develop a bicuspid, rather than tricuspid, aortic valve [68].
eNOS deficient mice with a BAV phenotype fed a high cholesterol diet develop hemody‐
namic symptoms of AS and also display microscopic mineralization in the aortic valve leaf‐
lets, indicating that eNOS activity may be important for suppressing aortic valve
calcification [178]. Nitric Oxide deficiency is also an indicator of endothelial cell dysfunction,
and systemic endothelial cell dysfunction is prevalent in patients with aortic valve sclerosis/
stenosis [223-225]. The uncoupling, or dysfunction, of eNOS results in decreased NO pro‐
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duction and increased generation of reactive oxygen species (ROS) [223]. ROS activity is
present in calcific lesions of human stenotic aortic valves, and it has been suggested that
ROS activity may speed aortic valve calcification [144, 226]. In animal studies, rabbits fed a
high cholesterol/high vitamin D diet develop aortic valve thickening, small deposits of valve
calcification, and increased ROS activity in cells surrounding regions of valve calcification
[226]. Furthermore, ROS activity was co-localized to clusters of cells expressing Runx2 and
OPN, suggesting that ROS activity is associated with VICs displaying an osteogenic-like
phenotype [226]. In VIC culture studies, TGFβ1 stimulation induces increased ROS activity,
along with calcific nodule formation and ALP activity [227]. Increasing the availability of
NO, via NO donors such as sodium nitroprusside, partially blocks both nodule formation
and ALP activity, suggesting that NO levels are important for reducing ROS and inhibiting
calcification in VICs [227]. There have been a number of small clinical studies investigating
the levels of the NOS inhibitor, asymmetric dimethylarginine (ADMA), an indicator of en‐
dothelial cell dysfunction, in patients with moderate to severe AS [228-230]. In these studies,
plasma levels of ADMA are significantly higher in patients with moderate to severe AS,
compared to patients with mild AS or no disease, suggesting that NO production is disrupt‐
ed in CAVD/AS [228-230]. Combined, these studies suggest that increased ROS production
is associated with aortic valve calcification and the induction of osteogenic gene expression.
Thus, increasing the bioavailability of NO may be a potential therapeutic avenue to block
ROS activity, and thereby disease progression, in CAVD.
5.6. NSAIDs/COX2 inhibitors
Previous reports have demonstrated that immune cell infiltration is common in CAVD [119,
132, 135]. Non-steroidal anti-inflammatory drugs (NSAIDS) are commonly used to treat
pain and inflammation, and act by inhibiting the enzymes COX1 and/or COX2 [231-233].
These enzymes function by converting arachidonic acid to prostaglandins (PGs) [233, 234].
There has been one study conducted in human aortic VICs, demonstrating that stimulation
of VICs with pro-inflammatory mimetics induces the expression of COX2 and the release of
prostaglandins [235]. This study suggests that COX2 inhibition may be one way to treat the
immune response associated with CAVD [235]. Interestingly, COX2 and PG signaling are al‐
so involved in bone formation as well as cellular responses to physical stress and strain,
processes that also likely contribute to CAVD (reviewed in [131]). In bone, PG signaling has
an anabolic effect, and PG treatment of osteoblast cultures results in increased expression of
OCN, BMP2, Runx2, OPN, ALP, and BSP [236-244]. In osteoblast cultures, BMP2 stimulation
induces COX2 expression through upregulation of Runx2, which binds to and activates the
COX2 promoter [245, 246]. Downstream, PG signaling induces the expression of p38 MAPK
through the activation of protein kinase A [243, 247]. Furthermore, fluid shear stress and
other physical forces induce COX2 expression in osteoblast-like cells, suggesting that in‐
creased COX2 and PG signaling is a cellular response to altered mechanical forces [248, 249].
The combined results of these studies suggest that COX2/PG signaling may be an effective
therapeutic target to treat CAVD progression, as COX2/PG signaling plays a role in inflam‐
mation, osteogenesis, and cellular response to physical strain, all of which are thought to be
pathological mechanisms involved in CAVD [131, 243, 244, 248-251]. It would be interesting
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to determine whether COX2 inhibition/NSAID use could reduce CAVD progression. How‐
ever, one caveat is that COX2 inhibitor therapy can be associated with some rare but signifi‐
cant adverse cardiovascular events such as myocardial infarction and stroke [252, 253].
Perhaps therapeutics designed toward downstream targets of PG signaling, such as p38
MAPK, could improve outcomes of CAVD patients without the cardiovascular side effects
of selective coxibs [254].
5.7. Development of new therapeutic approaches based on valvulogenic and osteogenic
molecular mechanisms.
As reviewed above, Notch, Wnt, and BMP signaling have been implicated in the progres‐
sion of CAVD. Pharmacotherapies designed to act as Wnt and BMP inhibitors, or Notch ag‐
onists, could be a potential avenue for new therapeutics to treat the progression of CAVD.
BMP signaling is thought to be a specific indicator of aortic valve calcification as active BMP
signaling is observed in adult diseased valves with prominent calcification and is not found
in pediatric diseased valves void of calcification [13]. Furthermore, BMP2 signaling stimu‐
lates VIC calcific nodule formation and induces osteogenic gene expression [138, 171]. It is
possible that therapies designed to inhibit BMP signaling will block osteogenic-like calcifica‐
tion in diseased aortic valves. Likewise, inhibition of the Wnt/β-catenin signaling pathway
may also serve to reduce aortic valve calcification during disease, which is supported by evi‐
dence from animal studies in ApoE knockout mice. When fed an atherogenic diet, ApoE
knockout mice reportedly develop aortic valve calcification, however, when the Wnt co-re‐
ceptor Lrp5 is genetically deleted in these mice, the amount of aortic valve calcification is
significantly reduced [180]. Therefore, Wnt inhibition may be another potential therapeutic
approach for treating CAVD. Lastly, strategies to maintain Notch signaling in the valves
may be another potential way to inhibit calcification in CAVD. Notch inhibition of calcifica‐
tion and osteogenic gene expression has been demonstrated in aortic VICs in culture and re‐
duced Notch signaling in vivo leads to CAVD in mice [65, 153, 175]. Furthermore, Notch1
haploinsufficiency in humans is associated with CAVD, indicating that maintaining Notch
signaling is important for valve homeostasis [64]. Thus, therapeutic strategies designed to
affect one or more of these pathways may serve to prevent valve calcification in CAVD. A
potential limitation of this approach is that BMP, Wnt, and Notch signaling pathways are
involved in many homeostatic and disease processes. For example, Wnt signaling is in‐
creased in many types of cancer, and all three pathways are involved in bone homeostasis.
Therefore the development of therapeutics based on these molecular mechanisms must take
into account potential effects on multiple organ systems. Nevertheless, targeted approaches
based on these pathways could represent a new therapeutic avenue in the development of
pharmacologic based approaches to CAVD.
6. Conclusions and future directions
There are numerous examples of shared molecular pathways between valvulogenesis, os‐
teogenesis, and disease pathogenesis of CAVD. In valvulogenesis, signaling factors involved
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in early cushion formation, such as BMP, Notch, and Wnt/β-catenin pathways are active in
osteogenesis and in CAVD [7-9, 14]. Furthermore, transcription factors expressed in the ear‐
ly valve mesenchyme, such as Twist1, Msx2, and Sox9, can also be found in the primitive
condensed bone mesenchyme and in the mesenchymal-like cells identified in diseased aortic
valve tissues [8, 13, 80, 255]. In addition to signaling and transcription factors, molecular
pathways governing ECM production and remodeling, such as the RANKL – NFATc1 –
CtsK pathway are shared amongst valve progenitor, developing bone, and diseased valve
tissues [11, 47, 103, 106, 193]. This commonality suggests that the mesenchymal cells found
within these tissues are governed by common molecular pathways and that these develop‐
mental pathways are reactivated during disease. Additional parallels can be drawn between
calcification of the embryonic bone tissues and calcification observed in diseased aortic
valves. For example, the endochondral bone factors Runx2, OCN, and BSP are reactivated
during aortic valve disease, suggesting that osteogenic molecular pathways are activated
during CAVD and may contribute to pathogenic calcification [5, 13, 76, 80, 106, 152]. Effec‐
tive pharmacological therapies to treat CAVD remain elusive and identifying potential tar‐
gets for new pharmacotherapies is a priority, as the only effective treatment for CAVD with
AS is valve replacement surgery [256]. Studies testing the effectiveness of statin therapy, in‐
hibitors of the renin-angiotensin-aldosterone, and bisphosphonates in slowing the progres‐
sion of CAVD have been disappointing (see therapeutic section). New therapeutic strategies
are needed and, perhaps, targeted inhibition of BMP and Wnt signaling or maintenance of
Notch signaling may provide new avenues for potential CAVD treatments.
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